Publicaciones en las que colabora con Antonio Rivero Juárez (11)

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  2. Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe

    Journal of Hepatology, Vol. 77, Núm. 2, pp. 326-331

2021

  1. Limited Value of Single Sampling for IgM Antibody Determination as a Diagnostic Approach for Acute Hepatitis E Virus Infection

    Microbiology Spectrum, Vol. 9, Núm. 1, pp. 1-5

2020

  1. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362

2019

  1. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  3. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy

    Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51

2018

  1. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 5, pp. 853-861

  2. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2014

  1. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients

    PLoS ONE, Vol. 9, Núm. 7